GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Portola Pharmaceuticals Inc (NAS:PTLA) » Definitions » Net Margin %

Portola Pharmaceuticals (Portola Pharmaceuticals) Net Margin % : -260.60% (As of Mar. 2020)


View and export this data going back to 2013. Start your Free Trial

What is Portola Pharmaceuticals Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Portola Pharmaceuticals's Net Income for the three months ended in Mar. 2020 was $-68.8 Mil. Portola Pharmaceuticals's Revenue for the three months ended in Mar. 2020 was $26.4 Mil. Therefore, Portola Pharmaceuticals's net margin for the quarter that ended in Mar. 2020 was -260.60%.

The historical rank and industry rank for Portola Pharmaceuticals's Net Margin % or its related term are showing as below:


PTLA's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -162.58
* Ranked among companies with meaningful Net Margin % only.

Portola Pharmaceuticals Net Margin % Historical Data

The historical data trend for Portola Pharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Portola Pharmaceuticals Net Margin % Chart

Portola Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,876.59 -757.78 -1,268.92 -872.72 -249.20

Portola Pharmaceuticals Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -352.55 -232.92 -134.86 -330.54 -260.60

Competitive Comparison of Portola Pharmaceuticals's Net Margin %

For the Biotechnology subindustry, Portola Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Portola Pharmaceuticals's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Portola Pharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where Portola Pharmaceuticals's Net Margin % falls into.



Portola Pharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Portola Pharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2019 is calculated as

Net Margin=Net Income (A: Dec. 2019 )/Revenue (A: Dec. 2019 )
=-290.663/116.64
=-249.20 %

Portola Pharmaceuticals's Net Margin for the quarter that ended in Mar. 2020 is calculated as

Net Margin=Net Income (Q: Mar. 2020 )/Revenue (Q: Mar. 2020 )
=-68.771/26.389
=-260.60 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Portola Pharmaceuticals  (NAS:PTLA) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Portola Pharmaceuticals Net Margin % Related Terms

Thank you for viewing the detailed overview of Portola Pharmaceuticals's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Portola Pharmaceuticals (Portola Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
270 E. Grand Avenue, South San Francisco, CA, USA, 94080
Portola Pharmaceuticals Inc is a biotechnology company focused on developing and commercializing novel therapeutics. The company focuses on areas of thrombosis, other hematologic disorders, and inflammation for patients who have limited or no approved treatment options. Portola focuses on biomarker or genetic approaches to clinical development that it believes will increase the probability of clinical, regulatory, and commercial success of first-in-class therapies. The company also uses collaborative agreements.
Executives
Dennis M Fenton director
John B Moriarty officer: EVP, General Counsel ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Hollings Renton director
David C Stump director
Ted W Love director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
John Johnson director DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Jeffrey W Bird director 755 PAGE MILL RD STE A-200, PALO ALTO CA 94304-1005
Henry Ward Wolff director 6701 KAISER DRIVE, FREMONT CA 94555
J. Scott Garland director, officer: President and CEO 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Laura Brege director C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608
Mardi Dier officer: EVP and CFO C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Rajiv Patni officer: EVP, CMO C/O OCERA THERAPEUTICS, INC., 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
John T Curnutte officer: EVP R&D PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Charles J Homcy other: Former Director PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
William Lis director, officer: Chief Executive Officer PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080

Portola Pharmaceuticals (Portola Pharmaceuticals) Headlines

From GuruFocus